KaliVir Secures $14 Million to Advance Oncology Pipeline
August 25, 2026, 9:38 am
KaliVir Immunotherapeutics secured $14M in Series A extension funding. Total Series A capital reached $25M. This bolsters clinical development for VET3-TGI. VET3-TGI is a lead oncolytic immunotherapy. It targets advanced solid tumors. Funds fuel the ongoing STEALTH-001 Phase 1/1b trial. KaliVir's proprietary VET platform is key. This platform enables multi-mechanistic agents. It destroys tumors. It activates the immune system. New investors joined the board. This strengthens KaliVir's balance sheet. It accelerates a promising approach against challenging cancers. The firm pushes vital clinical milestones.
KaliVir Immunotherapeutics recently closed a $14 million Series A extension. This funding boosts the company's financial strength. It brings KaliVir's total Series A capital to $25 million. This significant investment fuels critical clinical development. The primary focus is VET3-TGI, KaliVir's flagship oncolytic immunotherapy. This therapy targets advanced solid tumors.
The new capital directly supports the ongoing STEALTH-001 Phase 1/1b clinical trial. Patient enrollment will accelerate. Trial progress is essential. General corporate purposes also benefit. KaliVir, a Pittsburgh-based biotechnology firm, develops next-generation oncolytic immunotherapies. Its approach combines direct tumor targeting with potent immune-system activation.
VET3-TGI is an oncolytic virus. It leverages KaliVir's proprietary Vaccinia Enhanced Template (VET) platform. The VET platform is a powerful innovation. It engineers vaccinia virus backbones. Multiple genetic modifications are integrated. This design allows systemic delivery of oncolytic vaccinia candidates. Therapeutic transgenes express selectively within tumors. The platform’s versatility is a key advantage. It creates therapies with multiple mechanisms of action.
VET3-TGI specifically incorporates IL-12 and a TGFβ inhibitor. IL-12 stimulates immune responses. The TGFβ inhibitor counteracts immunosuppression. This combination enhances anti-tumor immune activity. The virus selectively replicates inside tumor cells. It spares healthy tissue. Local immune activity is stimulated. The immunosuppressive tumor microenvironment is altered. This multi-pronged attack is designed for efficacy.
The STEALTH-001 study is a crucial first-in-human trial. It is open-label. It involves dose-escalation and expansion phases. Patients have pathologically confirmed advanced, unresectable, or metastatic solid tumors. The trial evaluates VET3-TGI through two administration routes. Intratumoral injection is one method. Intravenous infusion is another. Both are critical for comprehensive assessment.
VET3-TGI is being tested as a monotherapy. It also combines with atezolizumab, a known immunotherapy. This dual approach explores synergistic effects. The study continues its dose-escalation phase. Progress aligns with original plans. Successful trial progression brings hope to patients.
Investor confidence remains strong. Company K Partners led the extension round. SV Investment and Flexus Partners also participated. Existing investors continued their support. These include affiliates of Nextrans and Quad Investment Management. Their continued backing validates KaliVir's platform and pipeline. This financing reflects optimism in the VET platform. It signals belief in VET3-TGI’s clinical progress.
The financing also strengthens KaliVir’s leadership team. Woo Young Kim of Company K Partners joined the board of directors. Kwang Ha Jung of SV Investment also took a board seat. JP Hong from Flexus Partners completed the new additions. These seasoned life sciences investors bring valuable insights. Their partnership will guide KaliVir's strategic growth.
Oncolytic immunotherapy represents a rapidly evolving field in cancer treatment. Traditional therapies often have severe side effects. They can struggle with tumor specificity. Oncolytic viruses offer a promising alternative. They target cancer cells directly. They also activate the body's own immune system. This dual action is powerful. It creates a lasting anti-tumor response.
Advanced solid tumors pose significant treatment challenges. Many patients exhaust standard options. New, innovative therapies are urgently needed. KaliVir's VET platform addresses this gap. It provides a robust framework. It develops potent and targeted therapies. The platform's ability to incorporate multiple genetic modifications is key. It allows for tailored therapeutic effects. This flexibility distinguishes KaliVir's approach.
The financial injection positions KaliVir to achieve key clinical milestones. It accelerates the evaluation of VET3-TGI. The therapy's potential as a differentiated oncolytic immunotherapy is clear. It offers a new weapon against aggressive cancers. The company's balance sheet is robust. This allows focus on science and patients. KaliVir aims to transform outcomes for patients battling advanced solid tumors. The future of cancer therapy looks brighter with such advancements.
KaliVir Immunotherapeutics recently closed a $14 million Series A extension. This funding boosts the company's financial strength. It brings KaliVir's total Series A capital to $25 million. This significant investment fuels critical clinical development. The primary focus is VET3-TGI, KaliVir's flagship oncolytic immunotherapy. This therapy targets advanced solid tumors.
The new capital directly supports the ongoing STEALTH-001 Phase 1/1b clinical trial. Patient enrollment will accelerate. Trial progress is essential. General corporate purposes also benefit. KaliVir, a Pittsburgh-based biotechnology firm, develops next-generation oncolytic immunotherapies. Its approach combines direct tumor targeting with potent immune-system activation.
VET3-TGI is an oncolytic virus. It leverages KaliVir's proprietary Vaccinia Enhanced Template (VET) platform. The VET platform is a powerful innovation. It engineers vaccinia virus backbones. Multiple genetic modifications are integrated. This design allows systemic delivery of oncolytic vaccinia candidates. Therapeutic transgenes express selectively within tumors. The platform’s versatility is a key advantage. It creates therapies with multiple mechanisms of action.
VET3-TGI specifically incorporates IL-12 and a TGFβ inhibitor. IL-12 stimulates immune responses. The TGFβ inhibitor counteracts immunosuppression. This combination enhances anti-tumor immune activity. The virus selectively replicates inside tumor cells. It spares healthy tissue. Local immune activity is stimulated. The immunosuppressive tumor microenvironment is altered. This multi-pronged attack is designed for efficacy.
The STEALTH-001 study is a crucial first-in-human trial. It is open-label. It involves dose-escalation and expansion phases. Patients have pathologically confirmed advanced, unresectable, or metastatic solid tumors. The trial evaluates VET3-TGI through two administration routes. Intratumoral injection is one method. Intravenous infusion is another. Both are critical for comprehensive assessment.
VET3-TGI is being tested as a monotherapy. It also combines with atezolizumab, a known immunotherapy. This dual approach explores synergistic effects. The study continues its dose-escalation phase. Progress aligns with original plans. Successful trial progression brings hope to patients.
Investor confidence remains strong. Company K Partners led the extension round. SV Investment and Flexus Partners also participated. Existing investors continued their support. These include affiliates of Nextrans and Quad Investment Management. Their continued backing validates KaliVir's platform and pipeline. This financing reflects optimism in the VET platform. It signals belief in VET3-TGI’s clinical progress.
The financing also strengthens KaliVir’s leadership team. Woo Young Kim of Company K Partners joined the board of directors. Kwang Ha Jung of SV Investment also took a board seat. JP Hong from Flexus Partners completed the new additions. These seasoned life sciences investors bring valuable insights. Their partnership will guide KaliVir's strategic growth.
Oncolytic immunotherapy represents a rapidly evolving field in cancer treatment. Traditional therapies often have severe side effects. They can struggle with tumor specificity. Oncolytic viruses offer a promising alternative. They target cancer cells directly. They also activate the body's own immune system. This dual action is powerful. It creates a lasting anti-tumor response.
Advanced solid tumors pose significant treatment challenges. Many patients exhaust standard options. New, innovative therapies are urgently needed. KaliVir's VET platform addresses this gap. It provides a robust framework. It develops potent and targeted therapies. The platform's ability to incorporate multiple genetic modifications is key. It allows for tailored therapeutic effects. This flexibility distinguishes KaliVir's approach.
The financial injection positions KaliVir to achieve key clinical milestones. It accelerates the evaluation of VET3-TGI. The therapy's potential as a differentiated oncolytic immunotherapy is clear. It offers a new weapon against aggressive cancers. The company's balance sheet is robust. This allows focus on science and patients. KaliVir aims to transform outcomes for patients battling advanced solid tumors. The future of cancer therapy looks brighter with such advancements.